Artelo Biosciences, Inc.
ARTL
$1.04
$0.010.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 53.56% | 5.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 219.00% | -52.43% | |||
| Operating Income | -219.00% | 52.43% | |||
| Income Before Tax | -233.75% | 53.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -233.75% | 53.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -233.75% | 53.47% | |||
| EBIT | -219.00% | 52.43% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -231.17% | 53.47% | |||
| Normalized Basic EPS | -216.51% | 52.43% | |||
| EPS Diluted | -231.17% | 53.47% | |||
| Normalized Diluted EPS | -216.51% | 52.43% | |||
| Average Basic Shares Outstanding | 0.77% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.77% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||